- Sanofi‘s Business EPS for the fourth quarter was €1.31, which missed the estimate of €1.34 and was down from €1.54 year-over-year.
- Sales were reported at €10.56 billion, a 9.1% increase from the previous year and above the estimated €10.41 billion.
- Key product sales included Dupixent at €3.46 billion, Beyfortus at €841 million, Aubagio at €78 million, and Influenza Vaccines at €454 million.
- When excluding foreign exchange effects, Dupixent sales increased by 16%, Beyfortus sales surged by 106.6%, Aubagio sales decreased by 35.5%, and Influenza Vaccines sales decreased by 36.8%.
- Biopharma net sales were €10.56 billion, with a 10.3% increase when excluding foreign exchange effects.
- Business net income was €1.64 billion, a 15% decrease year-over-year, missing the estimate of €1.67 billion.
- Business operating income matched the estimate at €2.08 billion, down 12% year-over-year.
- Biopharma Business operating income was €2.04 billion, a 13% decrease year-over-year.
- The gross margin was 74.3%, down from 76.8% the previous year, with Biopharma gross margin at 74% versus 76.6% year-over-year.
- R&D expenses increased by 24% year-over-year, reaching €2.26 billion.
- Free cash flow for the year was €2.34 billion.
- The dividend per share for 2024 was set at €3.92.
- Sanofi forecasts fiscal year sales to grow by a mid-to-high single-digit percentage at constant exchange rates.
- Expectations include a strong rebound in business EPS with low double-digit percentage growth at constant exchange rates, before share buybacks.
- Figures for 2023 have been restated to classify Opella as a discontinued operation.
“`
A look at Sanofi Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 4 | |
| Growth | 3 | |
| Resilience | 4 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Sanofi, a prominent pharmaceutical company, carries a positive long-term outlook based on its Smartkarma Smart Scores. With solid scores in Dividend, Resilience, and Momentum, the company demonstrates strength across these key factors. Sanofi‘s robust Dividend score reflects its ability to provide consistent returns to investors, while its high Resilience and Momentum scores indicate its capacity to weather challenges and maintain strong performance in the market.
Furthermore, Sanofi‘s Value and Growth scores, although not as high as the other factors, still contribute positively to its overall outlook. As a company that manufactures a range of prescription pharmaceuticals and vaccines, and develops medicines in various therapeutic areas, Sanofi‘s diversified portfolio positions it well for sustained growth and value creation in the long run.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
